Established Strength

AMIKACIN®
Amikacin Sulphate IV/IM

100mg, 250mg
500mg & 1gm
injection

AMIKACIN®

Amikacin Sulphate IV/IM

100mg, 250mg 500mg & 1gm injection

ECONOMY EFFICACY QUALITY ZAFA

The cost-effective treatment option that helps your patient get recover earlier

Common Clinical Uses of Amikacin

- *Complicated urinary tract infection*
- *Post-operative infections*
- *Severe pelvic inflammatory disease*
- *Neonatal sepsis*

A logical solution

- *Superior clinical results*
- *Active against Gentamycin resistant pathogens.*
- *Low bacterial resistance.*
- *Proven synergistic results.*
- *Affordable and economical*

Brief prescribing information

Description: Amikacin (Amikacin Sulphate) is a semisynthetic aminoglycoside antibiotic. **Indications:** Bacteremia and Septicemia, Neonatal sepsis, serious infections of respiratory tract, bones & joints, Central nervous system (including meningitis,) skin & soft tissue, intra abdominal infections (including peritonitis), burns, post-operative infections (including post vascular surgery) and serious complicated and recurrent UTI's caused by susceptible strains of bacteria. **Contraindications:** Hypersensitivity to Amikacin and aminoglycosides. **Precautions & Warnings:** Potential of causing ototoxicity, nephrotoxicity and neurotoxicity. Neuromuscular blockade and respiratory paralysis have been reported. Concurrent use of other cephalosporins increases nephrotoxicity. Patients should be well hydrated. **Caution:** Caution should be taken with myasthenia gravis or Parkinsonism, in pregnancy, premature neonates & infants and nursing mothers. **Adverse reactions:** Loss of hearing, balance, or both, acute muscular paralysis, apnea, elevated serum creatinine, albuminuria, oliguria and azotemia. **Dosage & administration:** Usual dose for adults, children and older infants with normal renal function is 15 mg/ kg/ day divided in 2 or 3 equal doses, in prematures 7.5 mg/ kg 12 hrly, in new born 10 mg/ kg as loading dose and 7.5 mg/ kg 12 hourly thereafter. Total daily dose should not exceed than 15 mg/ kg. In uncomplicated UTI a total dose of 500 mg/ day in single or two divided doses. In patients with renal impairment, dose should be adjusted according to creatinine clearance. **Presentation:** (100mg) (250mg) (500 mg) (1g in 4ml) intended for IM/IV administration.

"Medicines For All"

ZAFA Pharmaceutical Laboratories (Private) Limited

1-7/8, Block-22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI-75950 (PAKISTAN). Email: zafaph@cyber.net.pk Website: www.zafa.com.pk

ISO 9001:2000